Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1647 1675
This examiner grants 45% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18258397 | IL-2 MUTEINS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | Non-Final OA | MERCK SHARP & DOHME LLC |
| 17640177 | IL-22 ORAL, INTRA-RECTAL, OR OTHER GUT-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | AMGEN INC. |
| 17794917 | LIGAND-MEDIATED DELIVERY OF THERAPEUTIC PROTEINS AND THE USES THEREOF | Non-Final OA | Purdue Research Foundation |
| 18357007 | Antibodies Binding to Human PAD4 and Uses Thereof | Non-Final OA | Bristol-Myers Squibb Company |
| 18009083 | Agent for reversing resistance to anticancer drugs | Non-Final OA | JUNTENDO EDUCATIONAL FOUNDATION |
| 18253571 | METHODS AND COMPOSITIONS COMPRISING MHC CLASS PEPTIDES | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17632869 | DUAL BISPECIFIC ANTIBODY COMPOUNDS AND USES THEREOF | Final Rejection | CITY OF HOPE |
| 18267288 | ANTI-APRIL ANTIBODIES AND USES THEREOF | Non-Final OA | UNIVERSITÉ DE LAUSANNE |
| 18022669 | INTERLEUKIN-2 MUTEINS AND USES THEREOF | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 17596538 | Recombinant Interleukin 12 Construct and Uses Thereof | Final Rejection | Janssen Sciences Ireland Unlimited Company |
| 18282357 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | Non-Final OA | Dompe' Farmaceutici SPA |
| 18279014 | ANTI-NKP30 ANTIBODY AND APPLICATION THEREOF | Non-Final OA | Shenghe (China) Biopharmaceutical Co., Ltd. |
| 18268746 | STABLE ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | Non-Final OA | Bio-Thera Solutions, Ltd. |
| 17627025 | CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Final Rejection | SUNSHINE LAKE PHARMA CO., LTD. |
| 18315927 | SEPARATION MOIETIES AND METHODS OF USE THEREOF | Non-Final OA | Werewolf Therapeutics, Inc. |
| 18189619 | NOVEL PEPTIDE | Final Rejection | HYSENSBIO |
| 18113409 | MODIFIED IL-18 POLYPEPTIDES | Final Rejection | Bright Peak Therapeutics AG |
| 18002732 | ANTAGONISTIC PEPTIDE TARGETING IL-2, IL-9, AND IL-15 SIGNALING FOR THE TREATMENT OF CYTOKINERELEASE SYNDROME AND CYTOKINE STORM ASSOCIATED DISORDERS | Non-Final OA | Bioniz, LLC |
| 17784305 | CYTOKINE-BASED BIOACTIVATABLE DRUGS AND METHODS OF USES THEREOF | Final Rejection | Cugene Inc |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy